Resource impact statement
NICE has recommended glofitamab, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults after 2 or more systemic treatments. Glofitamab is only recommended if the company provides it according to the commercial arrangement.
We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 56.6 million people).
This is because the technology is a further treatment option and the overall cost of treatment for this patient group will be similar.
This statement is supported by a resource impact template which may be used to calculate the resource impact of implementing the guidance for glofitamab and the other treatment options. Because the treatment pathway for DLBCL has recently changed rapidly, organisations should complete both current and future uptake based on local practice.
Glofitamab and the other treatment options have discounts that are commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
This page was last updated: